A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE, PHASE III STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF TICAGRELOR AND ASA COMPARED WITH ASA IN THE PREVENTION OF STROKE AND DEATH IN PATIENTS WITH ACUTE ISCHAEMIC STROKE OR TRANSIENT ISCHAEMIC ATTACK [THALES - ACUTE STROKE OR TRANSIENT ISCHAEMIC ATTACK TREATED WITH TICAGRELOR AND ASA FOR PREVENTION OF STROKE AND DEATH
- Registry ID
- D5134C00003
- Source registry
- HEALTH_CANADA
- Status
- Closed
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- ASTRAZENECA CANADA INC
- Start date
- 2018-04-25
- Completion date
- 2019-12-13
- Last update
- 2017-12-06
Conditions
- ISCHEMIC ATTACK AND MINOR STROKE
Related clinical trials
- NUANCE-ICAD: EFFECT OF GENOTYPE-GUIDED ORAL P2Y12 INHIBITOR SELECTION VS CONVENTIONAL CLOPIDOGREL THERAPY IN SYMPTOMATIC INTRACRANIAL ATHEROSCLEROTIC DISEASE: A PILOT PROSPECTIVE, RANDOMIZED, OPEN-LABEL, BLINDED-ENDPOINT (PROBE) MULTI-CENTRE STUDY
- FOCAL CEREBRAL ARTERIOPATHY STEROID (FOCAS) TRIAL
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY TO DEMONSTRATE THE EFFICACY AND SAFETY OF MILVEXIAN, AN ORAL FACTOR XIA INHIBITOR, FOR STROKE PREVENTION AFTER AN ACUTE ISCHEMIC STROKE OR HIGH-RISK TRANSIENT ISCHEMIC ATTACK
- RANDOMIZED EFFICACY AND SAFETY TRIAL WITH ORAL S 44819 AFTER RECENT ISCHEMIC CEREBRAL EVENT INTERNATIONAL, MULTI-CENTRE, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED PHASE II STUDY
- A RANDOMIZED CONTROLLED TRIAL OF TNK-TPA VERSUS STANDARD OF CARE FOR MINOR ISCHEMIC STROKE WITH PROVEN OCCLUSION
- PLATELET-ORIENTED INHIBITION IN NEW TIA AND MINOR ISCHEMIC STROKE (POINT) TRIAL, A RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER CLINICAL TRIAL
View on source registry